Genomic Health News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.05.17	Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types (PR Newswire)
25.05.17	Genomic Health to Present at Jefferies 2017 Healthcare Conference (PR Newswire)
15.05.17	OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2017 (PR Newswire)
15.05.17	SimpliPhi Power AccESS Honored as a 2017 Energy Industry Innovation of the Year by Stevie Awards® (PR Newswire)
13.05.17	Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate... (PR Newswire)
12.05.17	Oncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease (PR Newswire)
09.05.17	Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress (PR Newswire)
04.05.17	Genomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score™ in Patients with Favorable Intermediate-risk... (PR Newswire)
04.05.17	Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases (PR Newswire)
02.05.17	Richard S. Isaacs, MD, to Assume Roles of Executive Director and CEO of The Permanente Medical Group and President and CEO of Mid-Atlantic Permanente Medical Group (PR Newswire)
02.05.17	Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017 (PR Newswire)
29.03.17	Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients (PR Newswire)
24.03.17	Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results (PR Newswire)
20.03.17	Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy (PR Newswire)
28.02.17	Genomic Health to Present at the Cowen and Company 37th Annual Health Care Conference (PR Newswire)
16.02.17	Four New Studies of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection (PR Newswire)
14.02.17	Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook (PR Newswire)
07.02.17	Genomic Health to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 14, 2017 (PR Newswire)
22.12.16	Genomic Health Announces Inclusion of Oncotype DX® in the 8th Edition of American Joint Committee on Cancer (AJCC) Criteria for Breast Cancer Staging (PR Newswire)
13.12.16	Credit Karma Expands U.S. Operations with Charlotte Office (PR Newswire)
29.11.16	Genomic Health Announces Presentation of Multiple Oncotype DX® Studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium, Reinforcing Value of Genomics in Precision Medicine (PR Newswire)
28.09.15	Genomic Reports Initial Results From TAILORx In Breast Cancer (RTTNews)
28.09.15	Genomic Says New Studies Establish Oncotype DX's Prospective Outcomes Data (RTTNews)
05.11.14	Genomic Health Q3 Loss Narrower Than Estimates, Revenue Misses; Stock Down 6% (RTTNews)
29.09.14	Genomic Announces Positive Results From Clinical Validation Study Of Oncotype DX (RTTNews)
08.08.14	Genomic Health Q2 Loss Widens (RTTNews)
05.02.14	Genomic Health Posts Q4 Loss (RTTNews)
25.09.13	NICE Recommends Genomic Health's Oncotype DX® Test To Guide Chemotherapy Treatment Decisions For Qualified Early-Stage Invasive Breast Cancer Patients (PR Newswire)
25.09.13	NICE Recommends Genomic Health's Oncotype DX® Test To Guide Chemotherapy Treatment Decisions For Qualified Early-Stage Invasive Breast Cancer Patients (PR Newswire)
23.08.13	Updated St. Gallen International Breast Cancer Guidelines, for the Second Time, Recognize Oncotype DX® as the Only Validated Multi-Gene Test Able to Predict Chemotherapy Benefit (PR Newswire)
07.08.13	Genomic Health to Present at the Canaccord Genuity 33rd Annual Growth Conference (PR Newswire)
31.07.13	Genomic Health Posts Q2 Loss - Quick Facts (RTTNews)
31.07.13	Genomic Health Announces Second Quarter 2013 Financial Results and Business Progress (PR Newswire)
24.07.13	Genomic Health to Announce Second Quarter 2013 Financial Results and Host Conference Call on Wednesday, July 31, 2013 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	30.37	2.88 %	K V
Part Grp Hldg	1’330.00	2.39 %	K V
Roche Hldg G	271.80	1.84 %	K V
Givaudan	3’941.00	1.52 %	K V
Novartis	91.64	0.75 %	K V
Geberit	502.80	-0.59 %	K V
CieFinRichemont	139.55	-0.99 %	K V
Swiss Re	133.25	-1.15 %	K V
Zurich Insur Gr	540.00	-1.32 %	K V
Kuehne+Nagel Int	203.00	-2.12 %	K V

Nachrichten zu Genomic Health IncShs

Aktien Top/Flop

Meistgelesene Nachrichten